Table of Content

1 Research Methodology

2 Research Objectives

3 Research Process


4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of the study
4.4 Market Segments
4.4.1 Market Segmentation by Products
4.4.2 Market Segmentation by Applications
4.4.3 Market Segmentation by Geography


5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation


6 Market at A Glance

7 Introduction
7.1 Iron Deficiency: An Overview
7.1.1 Symptoms of ID
7.1.2 Causes of ID
7.1.3 Treatment


8 Market Dynamics
8.1 Market Growth Enablers
8.1.1 Expanding Population Pool with Iron Deficiency
8.1.2 High Demand for Non-dextran IV Iron Therapeutics
8.1.3 Rising Demand Among Dialysis and Non-dialysis Patients
8.2 Market Growth Restraints
8.2.1 Adverse Events Associated with Oral & IV Iron Drugs
8.2.2 Presence of Alternative Options for Treating ID and IDA
8.2.3 Availability of Low-cost Generic Iron Drugs
8.3 Market Opportunities & Trends
8.3.1 Investigational Iron Drugs and Expected Approvals in Newer Markets
8.3.2 Increase in Strategic Collaborations and Licensing Opportunities
8.3.3 Availability of Branded Iron Therapeutics and Expanded Indication Approvals


9 Global IV & Oral Iron Drugs Market
9.1 Market Overview
9.2 Market Size & Forecast
9.3 Five Forces Analysis
9.3.1 Threat of New Entrants
9.3.2 Bargaining Power of Suppliers
9.3.3 Bargaining Power of Buyers
9.3.4 Threat of Substitutes
9.3.5 Competitive Rivalry


10 By Route Of Administration
10.1 Market snapshot & Growth Engine
10.2 Market Overview
10.3 Oral Iron Drugs
10.3.1 Market Overview
10.3.2 Market Size & Forecast
10.4 IV Iron Drugs
10.4.1 Market Overview
10.4.2 Market Size & Forecast


11 By Application
11.1 Market Snapshot & Growth Engine
11.2 Market Overview
11.3 Nephrology
11.3.1 Market Overview
11.3.2 Market Size & Forecast
11.4 Obstetrics and Gynecology (OBGYN)
11.4.1 Market Overview
11.4.2 Market Size & Forecast
11.5 Surgeries
11.5.1 Market Overview
11.5.2 Market Size & Forecast
11.6 Gastroenterology
11.6.1 Market Overview
11.6.2 Market Size & Forecast
11.7 Oncology
11.7.1 Market Overview
11.7.2 Market Size & Forecast
11.8 Heart failure
11.8.1 Market Overview
11.8.2 Market Size & Forecast

12 By Geography
12.1 Market Snapshot & Growth Engine
12.2 Market Overview


13 North America
13.1 Market Overview
13.2 Market Size & Forecast
13.3 Key Countries
13.3.1 US: Market Size & Forecast
13.3.2 Canada: Market Size & Forecast

14 Europe
14.1 Market Overview
14.2 Market Size & Forecast
14.3 Key Countries
14.3.1 Germany: Market Size & Forecast
14.3.2 UK: Market Size & Forecast
14.3.3 France: Market Size & Forecast
14.3.4 Spain: Market Size & Forecast
14.3.5 Italy: Market Size & Forecast


15 APAC
15.1 Market Overview
15.2 Market Size & Forecast
15.3 Key Countries
15.3.1 Japan: Market Size & Forecast
15.3.2 China: Market Size & Forecast
15.3.3 Australia: Market Size & Forecast
15.3.4 South Korea: Market Size & Forecast


16 Latin America
16.1 Market Overview
16.1.1 Market Size & Forecast
16.2 Key Countries
16.2.1 Brazil: Market Size & Forecast
16.2.2 Mexico: Market Size & Forecast

17 Middle-East And Africa
17.1 Market Overview
17.1.1 Market Size & Forecast
17.2 Key Countries
17.2.1 Turkey: Market Size & Forecast
17.2.2 Saudi Arabia: Market Size & Forecast


18 Competitive Landscape
18.1 Competition Overview


19 Key Vendors
19.1 Vifor Pharma Group
19.1.1 Business Overview
19.1.2 Vifor Pharma Group in Global IV & Oral Iron Drugs Market
19.1.3 Key Strategies
19.1.4 Key Strengths
19.1.5 Key Opportunities
19.2 Daiichi Sankyo Company
19.2.1 Business Overview
19.2.2 Major Product Offerings
19.2.3 Daiichi Sankyo Company in Global IV & Oral Iron Drugs Market
19.2.4 Key Strategies
19.2.5 Key Strengths
19.2.6 Key Opportunities

20 Prominent Vendors
20.1 AMAG Pharmaceuticals
20.1.1 Business Overview
20.1.2 Major Product Offerings
20.1.3 AMAG Pharmaceuticals in Global IV & Oral Iron Drugs Market
20.1.4 Key Strategies
20.1.5 Key Strengths
20.1.6 Key Opportunities
20.2 Akebia Therapeutics
20.2.1 Business Overview
20.2.2 Major Product Offerings
20.2.3 Key Strategies
20.2.4 Key Strengths
20.2.5 Key Opportunities
20.3 Shield Therapeutics
20.3.1 Business Overview
20.3.2 Major Product Offerings
20.3.3 Key Strategies
20.3.4 Key Strengths
20.3.5 Key Opportunities
20.4 Pharmacosmos
20.4.1 Business Overview
20.4.2 Major Product Offerings
20.4.3 Key Strategies
20.4.4 Key Strengths
20.4.5 Key Opportunities
20.5 Allergan
20.5.1 Business Overview
20.5.2 Major Product Offerings
20.5.3 Key Strategies
20.5.4 Key Strengths
20.5.5 Key Opportunities
20.6 Sanofi
20.6.1 Business Overview
20.6.2 Major Product Offerings
20.6.3 Key Strategies
20.6.4 Key Strengths
20.6.5 Key Opportunities
20.7 AOP Orphan Pharmaceuticals
20.7.1 Business Overview
20.7.2 Major Product Offerings
20.7.3 Key Strategies
20.7.4 Key Strengths
20.7.5 Key Opportunities


21 Other Vendors
21.1 Pfizer
21.1.1 Business Overview
21.1.2 Product Offerings
21.2 Sunny Pharmaceutical
21.2.1 Business Overview
21.2.2 Product Offerings
21.3 MEDICE
21.3.1 Business Overview
21.3.2 Product Offerings
21.4 AZAD Pharma
21.4.1 Business Overview
21.4.2 Product Offerings
21.5 Cirondrugs
21.5.1 Business Overview
21.5.2 Product Offerings
21.6 Salveo Lifecare
21.6.1 Business Overview
21.6.2 Product Offerings


22 Report Summary
22.1 Key Takeaways
22.2 Strategic Recommendations
22.3 Quantitative Summary
22.3.1 By ROA
22.3.2 By Application
22.3.3 By Geography


23 Appendix
23.1 Abbreviations

List of Exhibits
Exhibit 1 Segmentation of Global IV & Oral Iron Drugs Market
Exhibit 2 Market Size Calculation Approach 2018
Exhibit 3 Impact of Expanding Population Pool with Iron Deficiency
Exhibit 4 Prevalence Rate of Anemia in Infants and Young Children (0?5 years) 2015
Exhibit 5 Global Prevalence of Anemia in Different Population Groups
Exhibit 6 Percentage of Patients Affected with IDA in Various Diseases
Exhibit 7 Impact of High Demand for Non-dextran IV Iron Therapeutics
Exhibit 8 Vifor Pharma Group?s Ferinject Revenue 2016?2018 ($ million)
Exhibit 9 Daiichi Sankyo Company Ferinject Revenue 2015?2018 ($ million)
Exhibit 10 AMAG Pharmaceuticals? Feraheme 2016?2018 ($ million)
Exhibit 11 Impact of Rising Demand Among Dialysis and Non-dialysis Patients
Exhibit 12 Anemia Prevalence Rate Comparison Between General Population and CKD Patients
Exhibit 13 Revenue of Branded IV Iron Drugs Indicated for IDA in CKD Patients 2018 ($ million)
Exhibit 14 Impact of Adverse Events Associated with Oral & IV Iron Drugs
Exhibit 15 Impact of Presence of Alternative Options for Treating ID and IDA
Exhibit 16 Popular Alternative Options for Treating ID/IDA
Exhibit 17 Impact of Availability of Low-cost Generic Iron Drugs
Exhibit 18 Percentage Share of Prescription Iron Drugs by Region 2018
Exhibit 19 Impact of Investigational Iron Drugs and Expected Approvals in Newer Markets
Exhibit 20 Impact of Increase in Strategic Collaborations and Licensing Opportunities
Exhibit 21 Impact of Availability of Branded Iron Therapeutics and Expanded Indication Approvals
Exhibit 22 Global IV & Oral Iron Drugs Market by Application 2018 & 2024 (%)
Exhibit 23 Global IV & Oral Iron Drugs Market by ROA 2018 & 2024 (%)
Exhibit 24 Global IV & Oral Iron Drugs Market 2018?2024 ($ million)
Exhibit 25 Global IV & Oral Iron Drugs Market by Region: Market Snapshot
Exhibit 26 Global IV & Oral Iron Drugs Market by Geography: Incremental Growth
Exhibit 27 Global IV & Oral Iron Drugs Market by ROA: Incremental Growth
Exhibit 28 Global IV & Oral Iron Drugs Market by Application: Incremental Growth
Exhibit 29 Five Forces Analysis 2018
Exhibit 30 Incremental Growth by ROA 2018?2024
Exhibit 31 Global IV & Oral Iron Drugs Market by ROA 2018?2024 (%)
Exhibit 32 Global IV & Oral Iron Drugs Market by ROA Type: Absolute Growth
Exhibit 33 Global IV & Oral Iron Drugs Market 2018 & 2024 (%)
Exhibit 34 Global IV & Oral Iron Drugs Market 2018?2024 ($ million)
Exhibit 35 Global IV & Oral Iron Drugs Market 2018?2024 (%)
Exhibit 36 Maltofer Revenue 2017 & 2018 ($ million)
Exhibit 37 Feraccru Revenue 2016 & 2018 ($ million)
Exhibit 38 Global Oral Iron Drugs Market 2018?2024 ($ million)
Exhibit 39 Vifor Pharma Group?s Revenue for Ferinject/Injectafer 2016?2018 ($ million)
Exhibit 40 Daiichi Sankyo Group’s Revenue for Injectafer 2015?2018 ($ million)
Exhibit 41 Venofer Revenue 2017 & 2018 ($ million)
Exhibit 42 AMAG Pharmaceuticals’ Feraheme 2016?2018 revenue ($ million)
Exhibit 43 Global IV Iron Drugs Market 2018?2024 ($ million)
Exhibit 44 Incremental Growth by Application 2018?2024
Exhibit 45 Global IV & Oral Iron Drugs Market by Application Type
Exhibit 46 Global IV & Oral Iron Drugs Market by Application Type 2018 & 2024 (%)
Exhibit 47 Global IV & Oral Iron Drugs Market by Application: Incremental Growth
Exhibit 48 Global IV & Oral Iron Drugs Market by Application Type 2018?2024 ($ million)
Exhibit 49 Global IV & Oral Iron Drugs Market by Application Type 2018?2024 (%)
Exhibit 50 Global IV & Oral Iron Drugs Market by Application: Absolute Growth
Exhibit 51 Global IV & Oral Nephrology Iron Drugs Market 2018?2024 ($ million)
Exhibit 52 Global IV & Oral OBGYN Iron Drugs Market 2018?2024 ($ million)
Exhibit 53 Global IV & Oral Surgeries Iron Drugs Market 2018?2024 ($ million)
Exhibit 54 Global IV & Oral Gastroenterology Iron Drugs Market 2018?2024 ($ million)
Exhibit 55 Global IV & Oral Oncology Iron Drugs Market 2018?2024 ($ million)
Exhibit 56 Global IV & Oral HF Iron Drugs Market 2018?2024 ($ million)
Exhibit 57 Incremental Growth by Geography 2018?2024
Exhibit 58 Global IV & Oral Iron Drugs Market by Region
Exhibit 59 Global IV & Oral Iron Drugs Market by Geography: 2018 Market Shares (%)
Exhibit 60 Global IV & Oral Iron Drugs Market by Region: Incremental Growth (2018?2024)
Exhibit 61 Global IV & Oral Iron Drugs Market by Region 2018 & 2024 (%)
Exhibit 62 Global IV & Oral Iron Drugs Market by Region 2018?2024 ($ million)
Exhibit 63 Global IV & Oral Iron Drugs Market by Region 2018?2024 (%)
Exhibit 64 IV & Oral Iron Drugs Market in North America 2018 (%)
Exhibit 65 Prevalence of CKD in US 2001?2016 (%)
Exhibit 66 IV & Oral Iron Drugs Market in North America 2018–2024 ($ million)
Exhibit 67 Incremental Growth in North America 2018?2024
Exhibit 68 IV & Oral Iron Drugs Market in US 2018?2024 ($ million)
Exhibit 69 IV & Oral Iron Drugs Market in Canada 2018?2024 ($ million)
Exhibit 70 IV & Oral Iron Drugs Market in Europe 2018 (%)
Exhibit 71 IV & Oral Iron Drugs Market in Europe 2018–2024 ($ million)
Exhibit 72 Incremental Growth in Europe 2018?2024
Exhibit 73 IV & Oral Iron Drugs Market in Germany 2018–2024 ($ million)
Exhibit 74 IV & Oral Iron Drugs Market in UK 2018–2024 ($ million)
Exhibit 75 IV & Oral Iron Drugs Market in France 2018–2024 ($ million)
Exhibit 76 IV & Oral Iron Drugs Market in Spain 2018–2024 ($ million)
Exhibit 77 IV & Oral Iron Drugs Market in Italy 2018–2024 ($ million)
Exhibit 78 IV & Oral Iron Drugs Market in APAC 2018 (%)
Exhibit 79 IV & Oral Iron Drugs Market in APAC 2018–2024 ($ million)
Exhibit 80 Incremental Growth in APAC 2018–2024
Exhibit 81 IV & Oral Iron Drugs Market in Japan 2018–2024 ($ million)
Exhibit 82 IV & Oral Iron Drugs Market in China 2018–2024 ($ million)
Exhibit 83 IV & Oral Iron Drugs Market in Australia 2018?2024 ($ million)
Exhibit 84 IV & Oral Iron Drugs Market in South Korea 2018?2024 ($ million)
Exhibit 85 IV & Oral Iron Drugs Market in Latin America by Country 2018 (%)
Exhibit 86 IV & Oral Iron Drugs Market in Latin America 2018?2024 ($ million)
Exhibit 87 Incremental Growth in Latin America 2018–2024
Exhibit 88 IV & Oral Iron Drugs Market in Brazil 2018–2024 ($ million)
Exhibit 89 IV & Oral Iron Drugs Market in Mexico 2018–2024 ($ million)
Exhibit 90 IV& Oral Iron Drugs Market in MEA 2018?2024 ($ million)
Exhibit 91 Incremental Growth in MEA 2018–2024
Exhibit 92 IV & Oral Iron Drugs Market in Turkey 2018–2024 ($ million)
Exhibit 93 IV & Oral Iron Drugs Market in Saudi Arabia 2018–2024 ($ million)
Exhibit 94 Strategic Recommendations for Market Participants
Exhibit 95 Vifor Pharma Group: Ferinject/Injectafer Revenue Breakdown by Region 2018 (%)
Exhibit 96 Vifor Pharma Group: Ferinject/Injectafer Revenue 2016?2018 ($ million)
Exhibit 97 Venofer Net Sales 2017 & 2018 ($ million)
Exhibit 98 Maltofer Net Sales 2017 & 2018 ($ million)
Exhibit 99 Daiichi Sankyo Company Revenue Breakdown by Region FY2017 (%)
Exhibit 100 American Regent Revenue Breakdown by Business Units FY2016 & FY2017 (%)
Exhibit 101 Daiichi Sankyo Company’s Injectafer Revenue 2015-2017 ($ million)
Exhibit 102 Exhibit 57 Daiichi Sankyo Company’s Venofer Revenue 2016 & 2017 ($ million)
Exhibit 103 AMAG Pharmaceuticals Revenue 2016?2018 ($ million)
Exhibit 104 AMAG Pharmaceuticals Revenue by Drugs 2018 (%)
Exhibit 105 Feraheme Revenue 2016–2018 ($ million)
Exhibit 106 Akebia Therapeutics Revenue Breakdown FY2018 (%)
Exhibit 107 Shield Therapeutics’ Revenue 2016–2018 ($ million)
Exhibit 108 Allergan Revenue Breakdown by Business Segments FY2018 (%)
Exhibit 109 Sanofi Revenue Breakdown by Healthcare Area 2018 (%)
Exhibit 110 Sanofi Revenue Breakdown by Geographic Area 2018 (%)

List of Tables
Table 1 Key Caveats
Table 2 Currency Conversion 2013?2018
Table 3 Standard Requirement of Iron in Different Patient Groups
Table 4 Oral Iron Therapy: Advantages and Disadvantages
Table 5 IV Iron: Advantages and Disadvantages
Table 6 Characteristics of Oral and IV Iron Drugs
Table 7 Popular Prescription Drugs Used for Treating IDA in CKD Patients
Table 8 Most Popular Food Sources with High Iron Levels
Table 9 Investigational Iron Therapeutics Under Development
Table 10 Tentative Approval/Launch of Popular Iron Drugs in Various Countries/Regions
Table 11 Major Strategic Collaborations and Licensing Partnerships
Table 12 Major Iron Drugs Approved in Various Countries/Regions
Table 13 Expanded Indication Approvals for Already Commercialized IV & oral Iron Drugs
Table 14 Popular IV and Oral Iron Drugs Available
Table 15 Characteristics of Oran and IV Iron Drugs
Table 16 Most Common Oral Iron Drug Preparations
Table 17 Popular Branded Oral Iron Drugs Commercially Available
Table 18 Popular Branded IV Iron Drugs
Table 19 Popular Iron Drugs Available for Treating ID in CKD Patients
Table 20 Iron Supplementation Dosage Among Children
Table 21 Iron Therapy Recommendation for Different Stages of Iron Deficiency in Surgical Patients
Table 22 Recommendations on Iron Therapy for Anemia and ID in Cancer Patients
Table 23 Iron-Containing Proteins Altered in Heart Failure Patients
Table 24 Current Guideline Recommendations for IV Iron in Heart Failure Patients
Table 25 Popular Branded Iron Drugs Available in North America
Table 26 Popular Branded Iron Drugs Available in the US
Table 27 Popular Branded Iron Drugs Available in Canada
Table 28 Prevalence of ID and IDA in Major Europe Countries (EU15)
Table 29 Popular Branded Iron Drugs Available in Europe
Table 30 Competitive Structure Analysis of Global IV & Oral Iron Drugs Market 2018
Table 31 Global IV & Oral Iron Drugs Market: Vendors Ranking 2018
Table 32 Ranking of Vendors Offering Branded IV and Oral Iron Drugs
Table 33 Daiichi Sankyo Group R&D Pipeline Highlights (As of July 2018)
Table 34 Daiichi Sankyo Group’s Innovative Pharmaceuticals Business Key Products
Table 35 Daiichi Sankyo Company: Product Offerings
Table 36 AMAG Pharmaceuticals Marketed and Investigational Products Status
Table 37 AMAG Pharmaceuticals: Product Offerings
Table 38 Akebia Therapeutics: Product Offerings
Table 39 Shield Therapeutics: Pipeline Highlights
Table 40 Shield Therapeutics: Product Offerings
Table 41 Pharmacosmos: Product Offerings
Table 42 Allergan’s Recent Acquisitions
Table 43 Allergan: Product Offerings
Table 44 Sanofi: Product Offerings
Table 45 AOP Orphan Pharmaceuticals: Product Offerings
Table 46 Pfizer: Key Product Offerings
Table 47 Sunny Pharmaceutical: Key Product Offerings
Table 48 MEDICE: Key Product Offerings
Table 49 AZAD Pharma: Key Product Offerings
Table 50 Cirondrugs: Key Product Offerings
Table 51 Salveo Lifecare: Key Product Offerings
Table 52 Global IV & Oral Iron Drugs Market by Products ($ million)
Table 53 Global IV & Oral Iron Drugs Market by Products (%)
Table 54 Global IV & Oral Iron Drugs Market by Application ($ million)
Table 55 Global IV & Oral Iron Drugs Market by Applications (%)
Table 56 Global IV & Oral Iron Drugs Market by Geography ($ million)
Table 57 Global IV & Oral Iron Drugs Market by Geography (%)